Okskarbazepina (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Okskarbazepina" in Polish language version.

refsWebsite

Global rank Polish rank

17nih.gov

4^th place

7^th place

15doi.org

2^nd place

6^th place

1drugbank.ca

4,294^th place

205^th place

1sigmaaldrich.com

924^th place

75^th place

1ptfarm.pl

low place

4,900^th place

1web.archive.org

1^st place

1fda.gov

447^th place

1,118^th place

1wiley.com

222^nd place

228^th place

doi.org

dx.doi.org

Według niektórych źródeł aktywnym metabolitem jest esliskarbazepinam, por. C.C. Dulsat C.C. i inni, Eslicarbazepine acetate, „Drugs of the Future”, 34 (3), 2009, s. 189, DOI: 10.1358/dof.2009.034.03.1352675 (ang.).
J.A.J.A. French J.A.J.A. i inni, Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society, „Neurology”, 62 (8), 2004, s. 1252–1260, DOI: 10.1212/01.WNL.0000123693.82339.FC, PMID: 15111659 (ang.).
J.A.J.A. French J.A.J.A. i inni, Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society, „Neurology”, 62 (8), 2004, s. 1261–1273, DOI: 10.1212/01.WNL.0000123695.22623.32, PMID: 15111660 (ang.).
Maja A.M.A. Tomić Maja A.M.A. i inni, Synergistic Interactions Between Paracetamol and Oxcarbazepine in Somatic and Visceral Pain Modelsin Rodents, „Anesteshia and analgesia”, DOI: 10.1213/ANE.0b013e3181cbd8da, PMID: 20142344 (ang.).
Rajesh C.R.C. Sachdeo Rajesh C.R.C. i inni, Effects of oxcarbazepine on sodium concentration and water handling, „Ann Neurol”, 51 (5), 2002, s. 613–620, DOI: 10.1002/ana.10190, PMID: 12112108 (ang.).
Y.Y. Çetinkaya Y.Y. i inni, The Effect of Oxcarbazepine on Bone Metabolism, „Acta Neurol Scand”, 120 (3), 2009, s. 170–175, DOI: 10.1111/j.1600-0404.2008.01148.x, PMID: 19719808 (ang.).
HumbertoH. Saconato HumbertoH. i inni, Oxcarbazepine for refractory epilepsy: Systematic review of the literature, „São Paulo Medical Journal”, 127 (3), 2009, s. 150–159, DOI: 10.1590/S1516-31802009000300008, PMID: 19820875 (ang.).
JosephJ. Kwan JosephJ., EmmaE. Wood EmmaE., Antiepileptic drugs for the primary and secondary prevention of seizures after stroke, „Cochrane Database of Systematic Reviews”, 1, 2010, DOI: 10.1002/14651858.CD005398.pub2, PMID: 20091574 (ang.).
Robert M.A.R.M.A. Hirschfeld Robert M.A.R.M.A., SiegfriedS. Kasper SiegfriedS., A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder, „The International Journal of Neuropsychopharmacology”, 7 (4), 2004, s. 507–522, DOI: 10.1017/S1461145704004651, PMID: 15458610 (ang.).
M.F.M.F. Juruena M.F.M.F. i inni, Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial, „Prog Neuropsychopharmacol Biol Psychiatry”, 33 (1), 2009, s. 94–99, DOI: 10.1016/j.pnpbp.2008.10.012, PMID: 19007842 (ang.).
HeinzH. Grunze HeinzH., JörgJ. Walden JörgJ., Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder, „Journal of affective disorders”, 72, 2002, s. 15–21, DOI: 10.1016/S0165-0327(02)00339-7, PMID: 12589899 (ang.).
SilvioS. Bellino SilvioS., ErikaE. Paradiso ErikaE., FilippoF. Bogetto FilippoF., Oxcarbazepine in the Treatment of Borderline Personality Disorder: A Pilot Study, „The Journal of Clinical Psychiatry”, 66 (9), 2005, s. 1111–1115, DOI: 10.4088/jcp.v66n0904, PMID: 16187767 (ang.).
SilvioS. Bellino SilvioS., ErikaE. Paradiso ErikaE., FilippoF. Bogetto FilippoF., Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder, „CNS Drugs”, 22 (8), 2008, s. 671–692, DOI: 10.2165/00023210-200822080-00005, PMID: 18601305 (ang.).
D.E.D.E. Dietrich D.E.D.E., S.S. Kropp S.S., H.M.H.M. Emrich H.M.H.M., Oxcarbazepin in der Behandlung affektiver und schizoaffektiver Erkrankungen, „Fortschritte der Neurologie-Psychiatrie”, 71 (5), 2003, s. 255–264, DOI: 10.1055/s-2003-39065, PMID: 12740757 (niem.).
Joanna M.J.M. Zakrzewska Joanna M.J.M., Philip N.P.N. Patsalos Philip N.P.N., Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia, „Pain”, 95 (3), 2002, s. 259–266, DOI: 10.1016/S0304-3959(01)00406-7, PMID: 11839425 (ang.).

drugbank.ca

Oxcarbazepine, [w:] DrugBank [online], University of Alberta, DB00776 [dostęp 2022-07-30] (ang.).

fda.gov

Information for Healthcare Professionals: Suicidal Behavior and Ideation and Antiepileptic Drugs [online], U.S. Food and Drug Administration, 16 grudnia 2008 [dostęp 2010-04-14] [zarchiwizowane z adresu 2010-04-12] (ang.).

nih.gov

ncbi.nlm.nih.gov

J.A.J.A. French J.A.J.A. i inni, Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society, „Neurology”, 62 (8), 2004, s. 1252–1260, DOI: 10.1212/01.WNL.0000123693.82339.FC, PMID: 15111659 (ang.).
J.A.J.A. French J.A.J.A. i inni, Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society, „Neurology”, 62 (8), 2004, s. 1261–1273, DOI: 10.1212/01.WNL.0000123695.22623.32, PMID: 15111660 (ang.).
WandaW. Pakulska WandaW., ElżbietaE. Czarnecka ElżbietaE., Influence of oxcarbazepine on the antinociceptive action of morfine and metamizole in mice, „Acta Pol Pharm”, 66 (6), 2009, s. 715–722, PMID: 20050537 (ang.).
Maja A.M.A. Tomić Maja A.M.A. i inni, Synergistic Interactions Between Paracetamol and Oxcarbazepine in Somatic and Visceral Pain Modelsin Rodents, „Anesteshia and analgesia”, DOI: 10.1213/ANE.0b013e3181cbd8da, PMID: 20142344 (ang.).
Rajesh C.R.C. Sachdeo Rajesh C.R.C. i inni, Effects of oxcarbazepine on sodium concentration and water handling, „Ann Neurol”, 51 (5), 2002, s. 613–620, DOI: 10.1002/ana.10190, PMID: 12112108 (ang.).
Y.Y. Çetinkaya Y.Y. i inni, The Effect of Oxcarbazepine on Bone Metabolism, „Acta Neurol Scand”, 120 (3), 2009, s. 170–175, DOI: 10.1111/j.1600-0404.2008.01148.x, PMID: 19719808 (ang.).
HumbertoH. Saconato HumbertoH. i inni, Oxcarbazepine for refractory epilepsy: Systematic review of the literature, „São Paulo Medical Journal”, 127 (3), 2009, s. 150–159, DOI: 10.1590/S1516-31802009000300008, PMID: 19820875 (ang.).
JosephJ. Kwan JosephJ., EmmaE. Wood EmmaE., Antiepileptic drugs for the primary and secondary prevention of seizures after stroke, „Cochrane Database of Systematic Reviews”, 1, 2010, DOI: 10.1002/14651858.CD005398.pub2, PMID: 20091574 (ang.).
Robert M.A.R.M.A. Hirschfeld Robert M.A.R.M.A., SiegfriedS. Kasper SiegfriedS., A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder, „The International Journal of Neuropsychopharmacology”, 7 (4), 2004, s. 507–522, DOI: 10.1017/S1461145704004651, PMID: 15458610 (ang.).
M.F.M.F. Juruena M.F.M.F. i inni, Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial, „Prog Neuropsychopharmacol Biol Psychiatry”, 33 (1), 2009, s. 94–99, DOI: 10.1016/j.pnpbp.2008.10.012, PMID: 19007842 (ang.).
HeinzH. Grunze HeinzH., JörgJ. Walden JörgJ., Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder, „Journal of affective disorders”, 72, 2002, s. 15–21, DOI: 10.1016/S0165-0327(02)00339-7, PMID: 12589899 (ang.).
SilvioS. Bellino SilvioS., ErikaE. Paradiso ErikaE., FilippoF. Bogetto FilippoF., Oxcarbazepine in the Treatment of Borderline Personality Disorder: A Pilot Study, „The Journal of Clinical Psychiatry”, 66 (9), 2005, s. 1111–1115, DOI: 10.4088/jcp.v66n0904, PMID: 16187767 (ang.).
SilvioS. Bellino SilvioS., ErikaE. Paradiso ErikaE., FilippoF. Bogetto FilippoF., Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder, „CNS Drugs”, 22 (8), 2008, s. 671–692, DOI: 10.2165/00023210-200822080-00005, PMID: 18601305 (ang.).
D.E.D.E. Dietrich D.E.D.E., S.S. Kropp S.S., H.M.H.M. Emrich H.M.H.M., Oxcarbazepin in der Behandlung affektiver und schizoaffektiver Erkrankungen, „Fortschritte der Neurologie-Psychiatrie”, 71 (5), 2003, s. 255–264, DOI: 10.1055/s-2003-39065, PMID: 12740757 (niem.).
Joanna M.J.M. Zakrzewska Joanna M.J.M., Philip N.P.N. Patsalos Philip N.P.N., Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia, „Pain”, 95 (3), 2002, s. 259–266, DOI: 10.1016/S0304-3959(01)00406-7, PMID: 11839425 (ang.).

pubchem.ncbi.nlm.nih.gov

Oxcarbazepine, [w:] ChemIDplus [online], United States National Library of Medicine [dostęp 2022-07-30] (ang.).

dailymed.nlm.nih.gov

Warnings and precautions, [w:] Oxcarbazepine, Jubilant Cadista Pharmaceuticals, 2011 [dostęp 2014-04-08] (ang.).

ptfarm.pl

WandaW. Pakulska WandaW., ElżbietaE. Czarnecka ElżbietaE., Influence of oxcarbazepine on the antinociceptive action of morfine and metamizole in mice, „Acta Pol Pharm”, 66 (6), 2009, s. 715–722, PMID: 20050537 (ang.).

sigmaaldrich.com

Oxcarbazepine [online], karta charakterystyki produktu Sigma-Aldrich, 1 kwietnia 2022, numer katalogowy: O3764 [dostęp 2022-07-30] . (przeczytaj, jeśli nie wyświetla się prawidłowa wersja karty charakterystyki)

web.archive.org

Information for Healthcare Professionals: Suicidal Behavior and Ideation and Antiepileptic Drugs [online], U.S. Food and Drug Administration, 16 grudnia 2008 [dostęp 2010-04-14] [zarchiwizowane z adresu 2010-04-12] (ang.).

wiley.com

mrw.interscience.wiley.com

JosephJ. Kwan JosephJ., EmmaE. Wood EmmaE., Antiepileptic drugs for the primary and secondary prevention of seizures after stroke, „Cochrane Database of Systematic Reviews”, 1, 2010, DOI: 10.1002/14651858.CD005398.pub2, PMID: 20091574 (ang.).